BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, today announced that it was selected to present initial, first-in-human clinical results from the Phase 1/2 study of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place September 13 – 17, 2024 in Barcelona, Spain..

波士顿--（商业新闻短讯）--Scorpion Therapeutics，Inc.（“Scorpion”）是一家开创性的临床阶段肿瘤学公司，致力于通过重新定义精确肿瘤学的前沿来改变癌症患者的生活，今天宣布，它被选为在2024年9月13日至17日于西班牙巴塞罗那举行的2024年欧洲医学肿瘤学会（“ESMO”）大会上发表论文，在晚期实体瘤患者中首次展示STX-478（一种突变选择性PI3Kα抑制剂）的1/2期临床研究结果。。

“The presentation of first-in-human clinical data for our lead candidate, STX-478, marks an important milestone for patients living with advanced solid tumors driven by PI3Kα mutations, especially HR+/HER2- breast cancer, and for Scorpion as we work to broaden the reach and impact of precision oncology for patients with high unmet medical need,” said Mark Chao, M.D., Ph.D., Chief Medical Officer of Scorpion.

Scorpion首席医学官Mark Chao医学博士说：“我们的主要候选人STX-478的首次人体临床数据的发布，对于PI3Kα突变驱动的晚期实体瘤患者，尤其是HR+/HER2乳腺癌患者，以及Scorpion患者，标志着一个重要的里程碑，因为我们正在努力扩大精准肿瘤学对高度未满足医疗需求的患者的影响范围和影响。”。

“While PI3Kα has been one of the highest profile targets in cancer for years, current treatment options suffer from toxicity limitations and subpar efficacy due to a lack of mutant selectivity. These initial data will provide early insight into how STX-478's differentiated profile translates to potentially superior outcomes in PI3Kα-mutated cancers, and we look forward to presenting initial assessments of safety, pharmacokinetic and pharmacodynamic data and preliminary efficacy data at the ESMO 2024 Congress.'.

“虽然PI3Kα多年来一直是癌症中最受关注的靶点之一，但由于缺乏突变选择性，目前的治疗方案受到毒性限制和疗效不佳。这些初步数据将为STX-478的分化特征如何转化为PI3Kα突变癌症的潜在优越结果提供早期见识，我们期待在ESMO 2024大会上提交安全性，药代动力学和药效学数据以及初步疗效数据的初步评估。”。

Details of the Proffered Paper presentation are as follows:

提交的论文介绍详情如下：

Title: First-in-human Results of STX-478, a Mutant-selective PI3Kα Inhibitor, in Advanced Solid Tumor Patients

标题：突变选择性PI3Kα抑制剂STX-478在晚期实体瘤患者中的首次人体结果

Presentation Number: LBA27

演示编号：LBA27

Session Name: Proffered paper session 2: Developmental therapeutics (ID 156)

课程名称：提交的论文课程2：发展疗法（ID 156）

Session Date & Time: Sunday, September 15, 2024, at 14:45 CEST – 16:15 CEST (8:45 a.m. – 10:15 a.m. ET)

会议日期和时间：2024年9月15日，星期日，14:45 CEST–16:15 CEST（美国东部时间上午8:45–10:15）

Presentation Time: 14:55 CEST – 15:05 CEST (8:55 a.m. – 9:05 a.m. ET)

演示时间：美国东部时间14:55-15:05（美国东部时间上午8:55-9:05）

Location: Salamanca Auditorium - Hall 5

地点：萨拉曼卡礼堂-5号厅

Presenter: Alberto J. Montero, M.D. (University Hospitals Cleveland, OH, USA)

According to ESMO, the late-breaking abstract will be published via the ESMO website at 00:05 CEST on September 15 (6:05 p.m. ET on September 14). Data presented at the conference will be available to view in the 'Publications & Presentations' section of the Scorpion website (https://www.scorpiontx.com/publications-posters/) following the ESMO 2024 Congress..

。会议上提供的数据将可在Scorpion网站的“出版物和演示文稿”部分查看(https://www.scorpiontx.com/publications-posters/)在ESMO 2024年大会之后。。

About STX-478

关于STX-478

STX-478 was designed to improve outcomes in patients harboring PI3Kα mutations, one of the most prevalent drivers of cancer, occurring in over 166,000 patients per year with breast, gynecological and other solid tumors in the United States alone. In preclinical models, STX-478 demonstrated robust activity across a range of PI3Kα mutations while sparing wild-type PI3Kα inhibition in normal tissues; previous generations of non-selective PI3Kα inhibitors have limited patient benefit due to these on-target toxicities.

STX-478旨在改善PI3Kα突变患者的预后，PI3Kα突变是最常见的癌症驱动因素之一，仅在美国，每年就有超过166000名乳腺癌，妇科和其他实体瘤患者发生。在临床前模型中，STX-478在一系列PI3Kα突变中表现出强大的活性，同时保留了正常组织中野生型PI3Kα的抑制作用；。

Scorpion’s Phase 1/2 clinical trial is a multi-center, global, open-label study designed to evaluate the safety and tolerability of STX-478 in multiple ascending doses for patients with locally advanced or metastatic HR+/HER2- breast cancer and other solid tumors driven by PI3Kα mutations. The program entered the clinic in 2023 and has rapidly advanced, now in multiple expansion cohorts across a range of solid tumors and in breast cancer as monotherapy and in combinations with fulvestrant and CDK4/6 inhibitors.

Scorpion的1/2期临床试验是一项多中心，全球，开放标签研究，旨在评估STX-478在多次递增剂量下对局部晚期或转移性HR+/HER2-乳腺癌和其他实体瘤患者的安全性和耐受性。由PI3Kα突变驱动。该计划于2023年进入诊所，并迅速发展，目前已在一系列实体瘤和乳腺癌的多个扩展队列中作为单一疗法以及与氟维司群和CDK4/6抑制剂联合使用。

To learn more about the first-in-human trial of STX-478, please visit this page..

要了解有关STX-478首次人体试验的更多信息，请访问此页面。。

About Scorpion Therapeutics

关于蝎子疗法

Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer. Scorpion has built a proprietary and fully-integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets.

Scorpion是一家开创性的临床阶段肿瘤公司，它重新定义了精准医学的前沿，为更多的癌症患者提供优化和转化的治疗方法。Scorpion在癌症生物学、药物化学和数据科学领域建立了一个拥有最先进技术的专有和完全集成的平台，目标是始终如一地快速创建针对前所未有的靶标谱的精细选择性小分子化合物。

Scorpion aims to leverage its platform to advance a broad pipeline of wholly-owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets.

Scorpion旨在利用其平台，在三个目标类别中推进广泛的全资优化化合物渠道：针对经过验证的癌基因靶标的同类最佳分子；用于先前不可药用靶标的一流分子；以及用于新型癌症靶标的一流分子。

For more information, visit www.scorpiontx.com..

For more information, visit www.scorpiontx.com..